Anti-giant panda LIF monoclonal antibody, and hybridoma cell line, and use thereof

Abstract

The present invention discloses an anti-giant panda LIF monoclonal antibody, a hybridoma cell line, and use thereof, and belongs to the field of biotechnology. The antibody comprises a heavy chain variable region having an amino acid sequence set forth in SEQ ID NO. 1 and a light chain variable region having an amino acid sequence set forth in SEQ ID NO. 2. The hybridoma cell line LIF-2 is deposited at China Center for Type Culture Collection on Oct. 28, 2021 with the accession number of CCTCC NO: C202171. The anti-giant panda LIF monoclonal antibody developed by the present invention can accurately identify the target protein LIF, and lays an important foundation for LIF protein localization, tissue expression information, study on LIF and a receptor and a target cell thereof by using the high-specificity LIF monoclonal antibody and exploration of the effect of LIF in embryonic diapause in giant pandas.

Dependencies are inferred from the claim text.